COLL Q2 2022 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$124M+49.0% YoY

Gross Profit

$52M42.4% margin

Operating Income

$11M9.0% margin

Net Income

-$5M-4.2% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+47.5%

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

$40M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.0B

Stockholders' Equity

$198M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$124M	$83M	+49.0%
Gross Profit	$52M	$50M	+4.2%
Operating Income	$11M	$16M	-32.3%
Net Income	-$5M	$73M	-107.1%

Revenue Segments

Belbuca

$42M34%

Xtampza ER

$33M27%

Nucynta IR

$27M21%

Nucynta ER

$17M14%

Symproic

$4M3%

Other

$458,0000%

Elyxyb

$109,0000%